I ddechrau, ar ôl trafod ac ystyried y dystiolaeth, mae’r JCVI wedi argymell y dylid cynnig ail ddos o’r brechlyn i bobl ifanc 16-17 mlwydd oed nad ydynt mewn grŵp ‘risg uwch’.
Firstly, following discussion and consideration of the evidence, the JCVI has recommended that a second dose should be offered to young people aged 16–17 year olds, who are not in an ‘at-risk’ group.